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Transforming growth factor beta (TGF-b) family
ligands are pleotropic proteins with diverse cell-
type-specific effects on growth and differentiation.
For example, PAK2 activation is critical for the prolif-
erative/profibrotic action of TGF-b on mesenchymal
cells, and yet it is not responsive to TGF-b in epithelial
cells. We therefore investigated the regulatory
constraints that prevent inappropriate PAK2 activa-
tion in epithelial cultures. The results show that the
epithelial-enrichedproteinErbin controls the function
of the NF2 tumor suppressor Merlin by determining
the output of Merlin’s physical interactions with
activePAK2.Whereasmesenchymal TGF-b signaling
induces PAK2-mediated inhibition of Merlin function
in the absence of Erbin, Erbin/Merlin complexes
bind and inactivate GTPase-bound PAK2 in epithelia.
These results not only identify Erbin as a key determi-
nant of epithelial resistance to TGF-b signaling,
they also show that Erbin controls Merlin tumor
suppressor function by switching the functional
valence of PAK2 binding.
INTRODUCTION
Transforming Growth Factor beta (TGF-b) was first isolated as
a cytokine capable of stimulating normal anchorage-dependent
fibroblast cultures to form colonies under anchorage-indepen-
dent conditions (Keski-Oja et al., 1987; Roberts and Sporn,
1985). Although the ability to induce soft agar growth is a unique
property of TGF-b family members, further studies demon-
strated that the majority of cell types undergo a variety of
responses after TGF-b addition (Moses et al., 1990; Wakefield
and Sporn, 1990). This ability to generate distinct phenotypes
dependent upon the cell context is one of the most interesting,
yet enigmatic, aspects of TGF-b action.
The primary transcriptional effectors of TGF-b signaling are
two paralogs, Smad 2 and Smad 3 (Feng and Derynck, 2005;
Massague´ et al., 2005). Although the Smads are clearly impli-
cated in regulating many aspects of TGF-b family memberDevelosignaling, it is presently unclear how this (still) limited set of inter-
actions can result in such diverse cellular responses as growth
inhibition and/or growth stimulation. In that regard, a number
of publications have reported targets, including (but not limited
to) MAPK family members (ERKs, p38, JNKs), Bim, Ras, Rho
GTPases (Cdc42, Rac1, RhoA, RhoB), PI3K, PAK2, and c-Abl,
that can be activated by TGF-b receptors independent of the
Smad proteins and in a cell-type-specific manner (Moustakas
and Heldin, 2005; Rahimi and Leof, 2007). The mechanism(s)
regulating this cell tropism is not known, and although these
responses are operationally defined as non-Smad, there is often
crosstalk with the Smad pathway to obtain the full biologic
response (Flanders, 2004; Wilkes et al., 2003, 2005).
Of particular note is p21-activated kinase 2 (PAK2), which was
identified as being activated in response to TGF-b across
a number of fibroblast, but not epithelial, cell lines (Wilkes
et al., 2003). Activation occurs independently of Smad2 and
Smad3, reaches a peak around 60 min, and requires binding of
the GTP-loaded forms of Cdc42 or Rac1. Along with the Smad
cascade, PAK2 and its downstream target c-Abl are required
for the morphological transformation and proliferative response
observed in AKR-2B fibroblasts (Wilkes and Leof, 2006; Wilkes
et al., 2003). Moreover, we and others have extended these
in vitro phenotypes by documenting the critical role of this
non-Smad pathway in various in vivo models of organ fibrosis
(Azuma et al., 2007; Chaudhary et al., 2006; Daniels et al.,
2004; Wang et al., 2005).
PAK family kinases have been shown to mediate a wide range
a cellular events, from cytoskeletal rearrangements (Wilkes et al.,
2003) to growth promotion (Nheu et al., 2004) and cellular trans-
formation (Tang et al., 1998). The list of PAK substrates is
substantial, and a number depend on cell type and context
(Roig and Traugh, 2001). One protein reported to interact with
PAK kinases is the tumor suppressor Merlin (also called NF2 or
schwannomin), and absence or mutation of this gene results in
schwannoma (Kissil et al., 2003). Whereas homozygous Merlin
mutant embryos die in utero as a consequence of a failure to
gastrulate (Curto and McClatchey, 2008), the tumor-suppressive
function of Merlin appears to be more widespread than previ-
ously thought (Okada et al., 2007). For instance, loss of heterozy-
gosity and/or epigenetic mechanisms has implicated a role for
Merlin in melanoma, mesothelioma, and possibly colorectal
cancers. Although the mechanism(s) by which Merlin regulatespmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevier Inc. 433
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Merlin and Erbin Coregulate PAK2 ActivityFigure 1. Epithelial Lysate Contains a Factor(s) that Inhibits TGF-b-Stimulated PAK2 Activity and Binds Active, but Not Inactive, PAK2
(A) Fibroblast cell line AKR-2B (AKR) and (B) epithelial cell line Mv1Lu (M64) expressing tetracycline-inducible wild-type PAK2 (WT), dominant-negative PAK2
(DN), and constitutively active PAK2 (CA) were grown to confluence in the presence of 1 mg/ml doxycyclin. Cultures were serum starved for 24 hr and either
left untreated () or stimulated (+) with10 ng/ml TGF-b for 48 hr. Representative areas were photographed (203). The inserts in (B) show M64 + PAK2 CA clone
morphology after 96 hr ± TGF-b.
(C) Five untreated () AKR (fibroblast) and/or M64 (epithelial) lysates were mixed (with one box representing300 mg) at ratios varying from 5:0 AKR:M64 (lane 3)
to 0:5 (lane 8). The indicated combinations were then added to lysates (900 mg) prepared from stimulated AKR-2B cells for a total protein concentration of 2.4 mg.
After incubation at 4C for 5 min, PAK2 kinase activity (top), type I receptor kinase activity (2nd panel), Smad2 phosphorylation (3rd panel), and total Smad2
(bottom) were determined. Lanes 1 and 2 reflect untreated and TGF-b-stimulated AKR-2B cells (900 mg), respectively, prior to lysate addition.
(D) PAK2 kinase activity was determined in quiescent AKR cells (lane 1) or following 45 min of TGF-b treatment (lane 2). For lanes 3–5, untreatedM64 lysate (500mg)
was mixed with equivalent lysate from TGF-b-stimulated AKR cells (AKR +), and PAK2 activity was assessed (bottom panel). Lane 3 represents 100% of the ‘‘inhib-
itory activity’’ in the epithelial cell lysate, whereas lanes 4 and 5 depict the remaining ‘‘PAK2 inhibitory activity’’ after immunodepletion of Smad2 (lane 4) or PAK2
(lane 5) from the initial M64 lysate prior to mixing. The middle two panels show total Smad2 and PAK2 levels after immunodepletion of the indicated protein.
(E) PAK2 kinase activity was determined in lanes 1–3 as described for the analogous three lanes in (D). For lanes 4–6, unstimulated () or TGF-b-treated (+) AKR
lysates (500 mg) were used as a source of inactive and activated PAK2, respectively, and were added to equivalent M64 lysate. After mixing, the indicated lysate
was immunodepleted by using antibodies to the control protein GFP (lane 4) or PAK2 (lanes 5 and 6). Fresh AKR lysate (500 mg) was then added as a source of
active (AKR +) or inactive (AKR ) PAK2. This process of immunodepletion/readdition of fresh AKR lysate was repeated three times before the depleted lysates
(referred to as PAK2 Remaining; top panel) were mixed with 500 mg fresh stimulated AKR lysate (i.e., contains active PAK2) and assayed for PAK2 activity
(bottom panel). Total PAK2 in the mixed lysate (middle panel) was determined by western blot.proliferation is not completely understood, the ability of Merlin to
mediate contact inhibition via regulating Rho protein and PAK
signaling appears to be critical. To that end, Merlin has been
reported to act both as a direct substrate for PAK2 (Kissil
et al., 2002; Okada et al., 2005; Xiao et al., 2002), in which
COOH-terminal phosphorylation at S518 deactivates Merlin,
facilitating deregulated growth, and as an inhibitor of PAK activa-
tion (Kissil et al., 2003; Xiao et al., 2005).
A recently identified trans-acting negative regulator of
signaling is the LAP (for leucine-rich repeat and PDZ) family
member protein Erbin. Although Erbin was originally reported
as a binding partner for ErbB2 and was proposed as a mediator
of basolateral trafficking (Borg et al., 2000), over the past few
years the regulatory role(s) assigned to Erbin has become
increasingly complex. For instance, Erbin has been shown to (i)
directly bind p120-catenin family members (Izawa et al., 2002)
and the sodium/hydrogen exchanger regulatory factor-1,
NHERF1/EBP50 (Bretscher et al., 2000); (ii) link Merlin to adhe-
rens junctions (Rangwala et al., 2005); and (iii) suppress MAPK
signaling by binding Sur-8 and disrupting the Sur-8-Ras-Raf
complex (Dai et al., 2006; Huang et al., 2003; Rangwala et al.,
2005). Erbin has also been shown to bind Smads and affect their434 Developmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevietranscriptional output, although not their phosphorylation status
(Dai et al., 2007).
In this manuscript, we have addressed one of the mechanisms
by which cell-type-specific TGF-b signaling via PAK2 is
controlled. The data define distinct roles for Merlin depending
upon the cell context. In fibroblasts, in which PAK2 provides
a growth stimulatory signal, TGF-b treatment results in Merlin
phosphorylation/inactivation. However, in epithelial cells in
which PAK2 activity results in cell death, Merlin recruits the
epithelial-specific protein Erbin to activated PAK2 and disrupts
its interaction with GTP-loaded Rac1 or Cdc42 binding. These
studies indicate that Merlin and Erbin work in a coordinate
manner to help regulate context-specific cytokine action.
RESULTS
Epithelial Cells Contain a Dominant-Acting PAK2
Inhibitory Activity
TGF-b stimulates the activation of PAK2 in fibroblasts, but not
epithelial cells (Wilkes et al., 2003). Furthermore, PAK2 activity
is required for TGF-b morphologic transformation and colony
formation in soft agar (Figure 1A) (Wilkes et al., 2003). Thisr Inc.
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Merlin and Erbin Coregulate PAK2 Activitymesenchymal cell tropism generates a number of questions,
including how would an epithelial cell line respond to TGF-b in
the context of active PAK2? To address that issue, we selected
Mv1Lu cells stably expressing constitutively active PAK2
(Figure 1B) and examined their phenotype after TGF-b addition.
Although these cultures grew somewhat slower and had a slightly
altered morphology, in the absence of TGF-b the cells could be
continually passaged and could form a confluent monolayer (Fig-
ure 1B and data not shown). However, a 24–96 hr treatment with
TGF-b resulted in a profound morphologic change and signifi-
cant loss of viability (Figure 1B). Since TGF-b plays a crucial
role in normal epithelial homeostasis, these findings clearly
document a critical need to prevent inappropriate PAK2 activa-
tion. As these lines showed appropriate PAK2 kinase activity
and no detectable impact on Smad2 phosphorylation (see
Figure S1 available online), studies were initiated to investigate
the mechanism(s) by which TGF-b induces PAK2 activity in
mesenchymal cells, but not epithelial cells.
Preliminary experiments showed that epithelial lysates acted in
a dominant manner to inhibit TGF-b-induced PAK2 kinase activity
in fibroblast lysates (data not shown). As shown in Figure 1C, the
epithelial cell ‘‘inhibitory activity’’ is titratable and maximally
inhibits PAK2 activity when approximately equivalent amounts
of TGF-b-activated (i.e., fibroblast) and inhibitor (i.e., epithelial)
lysates are used (i.e., compare lanes 5 and 6 with lanes 2 and 3).
Non TGF-b-treated AKR lysate () was used to normalize for
equal protein and ensure that any observed loss in PAK2 activity
was not simply an inability to precipitate all activated PAK2 in the
TGF-b-treated AKR lysate. Likewise, lysate mixing had no effect
on the degree of Smad2 phosphorylation or on the kinase activity
of the type 1 receptor (Figure 1C). The epithelial inhibitor is trypsin
sensitive and is present irrespective of either the proliferative
state of the epithelial cultures or whether they have been treated
with TGF-b (data not shown). Since epithelial cells express PAK2
(Wilkes et al., 2003), we next investigated whether the inability of
TGF-b to stimulate PAK2 activity in epithelia reflected an associ-
ation of the inhibitor with PAK2. Contrary to our expectation,
immunodepletion of PAK2 (and presumably any associated
inhibitor) under a number of lysis conditions failed to remove
the inhibitory activity in the epithelial lysates (Figure 1D, compare
lane 5 with lanes 2 and 3). As these findings suggest that the inhib-
itor(s) is not associated with inactive PAK2, we examined whether
active PAK2 binds the inhibitor. In fact, Figure 1E shows that the
PAK2 inhibitory activity present in the initial epithelial lysates can
be removed by addition of fibroblast lysate containing active
PAK2 (compare lane 5 with lane 3). However, immunodepletion
with an irrelevant antibody (anti-GFP, lane 4) or with fibroblast
lysate consisting of inactive PAK2 (cells not treated with TGF-b,
lane 6) was unable to remove the inhibitory activity (compare
lanes 4 and 6 with lane 3). Documentation of the effectiveness
of PAK2 immunodepletion and the extent of PAK2 resupplemen-
tation is shown in the middle top and bottom panels, respectively.
These findings are consistent with the hypothesis that the ‘‘inhib-
itory activity’’ acts via binding activated PAK2.
PAK2 Inhibitory Activity in Epithelial Cultures Is
Mediated via the Interaction of Merlin and Erbin
Determining that ‘‘the inhibitor’’ binds to active PAK2 (Figure 1E)
provides a number of approaches by which it might be purified.DeveloWe first investigated whether a known PAK2 interactor might
play some role in the inhibition. One such protein that associates
with PAK isoforms is the NF2 tumor suppressor, Merlin (Kissil
et al., 2003). However, the documented relationship between
PAK proteins and Merlin is unclear, as Merlin has been described
as a substrate for PAK2 as well as a PAK inhibitor, depending on
the cell context and conditions. Nevertheless, the known func-
tion of Merlin as a tumor suppressor suggested that it might
have a fundamental role in the inhibitory response of epithelial
cells to TGF-b. In that regard, initial in vivo observations indi-
cated Merlin was indeed phosphorylated on Ser518 in AKR-2B
fibroblasts (which inactivates Merlin) in response to TGF-b, but
not in M64 epithelial cells that are growth inhibited (Figure 2A).
Although the effect of TGF-b on Merlin phosphorylation is
consistent with the hypothesis that Merlin is responsible for the
inhibitory activity in the epithelial cell lysate, further analysis sug-
gested the involvement of an associated protein(s). First, as
Merlin would only coimmunoprecipitate with activated PAK2,
no Merlin/PAK2 association could be identified in epithelial cells
(Figure 2A); and most importantly, second, Merlin has been
primarily shown to prevent PAK activation by binding the p21-
binding domain (although it was not excluded that Merlin could
also inhibit preactivated PAK2) (Kissil et al., 2003). However,
our assay selects for a protein that inhibits PAK2 already acti-
vated by prior TGF-b treatment. As such, although Figure 2A
clearly implies a role for Merlin, it was unlikely to be solely
responsible for the inhibition in PAK2 kinase activity. In order
to determine whether epithelial-specific Merlin-binding proteins
might contribute to this function, we immunoprecipitated Merlin
from AKR and M64 cell lysates and detected bound proteins by
silver stain (Figure 2B, left panel). One protein, of180 kDa (indi-
cated by an arrow and shown to be Erbin by mass spectrometry
analysis), was detected in the M64 lysate that was not similarly
observed bound to Merlin in the fibroblast lysate. The signifi-
cance of the smaller 160 kDa protein expressed in AKR, but
not M64, cells is currently unclear. To further document the asso-
ciation depicted in the silver stain, Erbin/Merlin binding was
confirmed by using GST-Merlin to pull down Erbin from an
epithelial cell lysate as well as by coimmunoprecipitation/
western analysis (Figure 2B, right panels) with two distinct Merlin
antibodies. Although Erbin had originally been identified as an
ErbB2-binding protein involved in basolateral receptor traf-
ficking, recent studies have shown that it is capable of binding
Merlin and functioning as an inhibitor of Ras and Nod-2 signaling
(Dai et al., 2006; McDonald et al., 2005; Rangwala et al., 2005).
We then examined the levels of Erbin and Merlin in three repre-
sentative fibroblast and epithelial cell lines to determine if Erbin
showed an epithelial cell tropism. As shown in Figure 2C,
although Merlin was expressed at a similar or greater extent in
the fibroblast lines compared to the epithelial cells, Erbin expres-
sion was significantly less in the fibroblast cultures, consistent
with the idea that Merlin/Erbin interactions prevent TGF-b from
inducing PAK2 kinase activity in epithelial cells. In fact, immuno-
depletion of either Merlin or Erbin abolished the PAK2 inhibitory
activity present in the epithelial lysate (Figure 3A, bottom panel,
compare lanes 5 and 6 with lane 3 and the control lane, 2),
whereas depletion of Smad2 was without effect (compare
lane 4 with lane 3). As would be expected by the association of
Erbin and Merlin (Figure 2B), immunodepletion of either led topmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevier Inc. 435
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Merlin and Erbin Coregulate PAK2 ActivityFigure 2. Association of Merlin with the
Epithelial-Enriched Protein Erbin
(A) Quiescent AKR or Mv1Lu (M64) cells were left
untreated () or stimulated (+) for 45 min with
10 ng/ml TGF-b. Immunoprecipitation (IP) and/or
western blot (WB) was performed with antibodies
to phospho-Ser518 Merlin, Merlin, or PAK2 as
indicated.
(B) Merlin was immunoprecipitated (IP) from AKR or
M64 cells, and associated proteins were detected
by silver stain after SDS-PAGE. The arrow depicts
an 180 kDa band associated with Merlin from
M64 cells. (Right top) Lysates from AKR (1940 mg)
or M64 (440 mg) cells were passed over GST beads
alone or GST-Merlin (GST-M), and bound protein
was western blotted for Erbin. The bottom panel
reflects Erbin levels in AKR (88 mg) and M64 (20 mg)
cellular lysate. A total of 4.43more AKR protein was
used to normalize for Erbin expression between
mesenchymal and epithelial cultures (see [C]).
(Right bottom) AKR and M64 cells were lysed and
immunoprecipitated with Merlin (top two panels) or
Erbin (bottom two panels) antibodies, and associ-
ated Merlin or Erbin was determined by western
blot (WB) analysis. Two different Merlin antibodies
(Merlin, Santa Cruz sc-331; Merlin2, Cell Signaling
#9168) were used to provide additional assurance
of the identity of the Erbin-associated protein.
(C) Fibroblast cell lines AKR-2B, Swiss3T3, and NIH 3T3, along with epithelial cell lines LLC-pk1, MDCK, and Mv1Lu, were grown to confluence, serum starved
overnight, and either left untreated () or stimulated (+) with 10 ng/ml TGF-b for 45 min. Equivalent protein (120 mg) was assessed for total Erbin (top), Merlin
(middle), or GAPDH (bottom) by western blot.a corresponding loss of the other (Figure 3A, middle panels).
Depletion of Smad2, however, had no effect on either Erbin or
Merlin levels, consistent with Smad and PAK2 signaling being
independently regulated (Wilkes et al., 2003).
To directly determine whether Erbin was the critical compo-
nent in the epithelial lysate responsible for the PAK2 inhibitory
activity, purified Erbin was added to a lysate prepared from
TGF-b-treated fibroblasts, and the effect on PAK2 kinase activity
was determined. As shown in Figure 3B (top panel), addition of
Erbin (but not Smad2) to fibroblast lysates had similar PAK2
inhibitory activity as the epithelial cell lysate mixing experiments
presented previously (i.e., compare Figures 1C–1E and 3A with
Figure 3B). This does not reflect a nonspecific action as Erbin
had no effect on Smad3 phosphorylation (Figure 3B, bottom
panel). Although Figures 1C and 3B clearly show that the PAK2
inhibitory activity mediated by epithelial lysates or Erbin, respec-
tively, has no effect on Smad phosphorylation, to further address
the specificity of this response, two additional questions were
investigated. First, would Erbin inhibit the kinase activity of the
related PAK1 protein; and, second, was in vivo expression of
Erbin in fibroblasts sufficient to prevent PAK2 activity after
TGF-b stimulation? Since PDGF stimulation results in the activa-
tion of both PAK1 and PAK2, purified Erbin was added to lysates
prepared from PDGF- or TGF-b-treated fibroblasts, and the
effect on PAK kinase activity was determined. Figure 3C shows
that although Erbin addition to PDGF- or TGF-b-treated cell
lysates inhibits PAK2 activity (bottom panel, compare lane 5
with lane 2 and lane 6 with lane 3), it has no effect on PDGF-
stimulated PAK1 (top panel, compare lane 5 with lane 2). As
expected, TGF-b does not activate PAK1 (top panel, lanes 3
and 6) (Wilkes et al., 2003), and addition of Smad2 (instead of436 Developmental Cell 16, 433–444, March 17, 2009 ª2009 ElsevieErbin) has no effect on either PAK2 or PAK1. Identical results
were observed when PAK1 activity was assessed in AKR cells
overexpressing Erbin (data not shown; see Figure 4). Thus, the
inhibitory effect of Erbin distinguishes growth factor-activated
PAK2 from the related PAK1 protein.
The previous studies have all used some in vitro approach to
assess the PAK2 inhibitory activity initially observed in epithelial
cell lysates. If, however, Erbin has a central role in cell-type-
specific TGF-b signaling, and TGF-b can activate PAK2 in fibro-
blasts due to low Erbin levels (Figure 2C), then expression of
Erbin in fibroblasts should prevent TGF-b from activating
PAK2. As such, PAK2 kinase activity was determined in AKR-2B
cells transiently transfected with either an Erbin or Smad2
expression vector. Whereas Smad2 had no effect on the activity
of cotransfected PAK2 (Figure 3D, compare lane 4 with lane 2),
the Erbin vector completely abrogated PAK2 activation by
TGF-b (Figure 3D, compare lane 6 with lane 2). To further inves-
tigate the direct in vivo effect of Erbin as well as the Erbin/Merlin
relationship, AKR-2B clones were selected stably expressing
Erbin (A-Erbin) or control vector (A-Hygro) in the presence or
absence of siRNA to Merlin. As expected, although A-Erbin cells
were unable to induce PAK2 activity and showed Erbin associ-
ated with PAK2 after TGF-b treatment, no effect on Smad2 or
Smad3 phosphorylation was observed (Figure 4A). However,
consistent with our previous data (Figures 2 and 3A) indicating
a role for Merlin (as well as Erbin) in preventing PAK2 activity in
epithelial cells, Merlin knockdown abrogated the inhibitory
effects of Erbin expression on PAK2 (Figure 4A, top panel).
These biochemical analyses were next extended to examine
both biologic and transcriptional responses regulated by TGF-b.
Inagreementwithour previousstudy demonstrating a requirementr Inc.
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Merlin and Erbin Coregulate PAK2 ActivityFigure 3. Erbin Inhibits PAK2 Kinase
Activity In Vitro and In Vivo
(A) Untreated M64 lysates (500 mg) were left
untreated (lane 3) or immunodepleted of Smad2
(lane 4), Merlin (lane 5), or Erbin (lane 6) before mix-
ing at a 1:1 ratio with lysates prepared from TGF-
b-treated (+) AKR cells and were assayed for
PAK2 activity. Prior to mixing, an aliquot (50 mg)
was western blotted for Smad2, Merlin, and Erbin
to document specific immunodepletion (middle
panels). Lanes 1 and 2 depict basal and TGF-
b-stimulated PAK2 activity, respectively, in AKR
cells observed in the absence of M64 lysate.
(B) Lysates (800 mg) were prepared from AKR-2B
cells either left untreated () or stimulated (+) for
45 min with 10 ng/ml TGF-b as described.
Smad2 or Erbin was purified from M64 cells by
catch and release, and 5 mg was added to the
indicated lysates; Blank represents no additions.
After incubation at 4C for 5–30 min, an in vitro
kinase reaction on immunoprecipitated PAK2
(top panel, 750 mg) or phospho-Smad3 western
(bottom panel, 50 mg) was performed.
(C) AKR cells were left untreated (, lanes 1 and 4)
or stimulated for 45 min with 25 ng/ml PDGF AB
(P, lanes 2 and 5) or 10 ng/ml TGF-b (b, lanes 3
and 6), and lysates (600 mg) were prepared.
Smad2 or Erbin was purified as described in (B),
and 10 mg of each was added to the indicated lysates (i.e., Smad2 added to lanes 1–3 and Erbin to lanes 4–6). After incubation at 4C for 5–30 min, an
in vitro kinase reaction on immunoprecipitated PAK1 (top panel) or PAK2 (bottom panel) was performed.
(D) AKR-2B cells were transiently transfected with eGFP-PAK2 alone or together with expression vectors for Smad2 (Flag-Smad2) or Erbin (Myc-Erbin). Cultures
were grown to confluence, serum starved overnight, and incubated at 37C for 45 min in the absence () or presence (+) of 10 ng/ml TGF-b. Samples were
assayed for eGFP-PAK2 kinase activity after IP with antibodies to GFP (top panel) or western blotted for eGFP-PAK2, Myc-Erbin, or Flag-Smad2.for PAK2 signaling in TGF-b morphologic transformation and
proliferation (Wilkes et al., 2003), Erbin expression prevented any
significant change in morphology or induction of anchorage-in-
dependent growth after TGF-b treatment (Figures 4B and 4C,
respectively). Similarly, the induction of PAK2-dependent tran-
scriptional targets suchasfibronectinand collagen type1 waspre-
vented in the A-Erbin cells, and, in accord with the recent findings
of Dai et al. (2007), Erbin also diminished Smad-dependent
reporter activity (Figure 4D). Although these findings clearly impli-
cate a role for Erbin as a negative regulator of TGF-b signaling, the
mechanism(s) by which Erbin impacts these various responses is
distinct. For instance, whereas the effect of Erbin on events such
as morphologic transformation, soft agar growth, and matrix
gene expression is proposed to occur via association with Merlin
(Figures 2 and 3A) (Wilkes et al., 2003), inhibition of Smad activity
is reported to be through direct binding (Dai et al., 2007). Consis-
tent with these two models, Merlin knockdown abrogated the
inhibitory impact of Erbin on PAK2-dependent TGF-b signaling
(Figures 4B–4D), yet it had no effect on either the Smad-regulated
SBE or 3TP reporters (Figure 4D).
Erbin Disrupts Cdc42/Rac1 Binding to PAK2
PAK2 is activated via both Rho protein-dependent and -inde-
pendent mechanisms (Roig and Traugh, 2001). As TGF-b stimu-
lated PAK2 activation is under a number of regulatory controls,
including both GTP loading and PAK2 binding of Cdc42 and
Rac1 (Wilkes et al., 2003, 2005), we investigated the specific
mechanism by which Erbin impacted PAK2 activity.DeveloOur previous studies showed that the inhibitory complex only
associates with active PAK2 (Figure 1E). As the binding of acti-
vated Rho proteins by group I PAK kinases is believed to be crit-
ical for PAK activation (Jaffer and Chernoff, 2002; Roig and
Traugh, 2001), we first confirmed that activation of Cdc42 and
Rac1 is not affected by Erbin (Figure 5C). However, we also
found that Erbin nonetheless specifically affects GTPase-
dependent (i.e., TGF-b or PDGF induced), but not GTPase-inde-
pendent (methylglyoxal, NaCl, or sphingosine-induced), PAK2
activation (Figure 5A). Moreover, a PAK2 point mutant with
constitutive kinase activity independent of Rho protein binding
(Fryer and Field, 2005; Zhao and Manser, 2005) was unaffected
by Erbin expression, yet PAK2 activation by transfection of
constitutively active Cdc42 or Rac1 was prevented in A-Erbin
cells (Figure 5B; left and right panels, respectively). Together,
these findings support the premise that Erbin regulates PAK2
activity by affecting a Rho protein-dependent mechanism(s),
subsequent to the initial activation of PAK2 by GTP-loaded
Rac1 or Cdc42. In fact, studies performed in AKR clones stably
overexpressing Erbin or in lysates prepared from TGF-b-treated
AKR cells (Figure 5C; 2nd and 5th panels, respectively) showed
that Erbin stimulates a loss of PAK2 from Cdc42 or Rac1
complexes. The data suggest that rather than preventing Rho
protein activation or PAK2 association, Erbin inhibits the mainte-
nance of PAK2 kinase activity by dissociating PAK2 from acti-
vated Cdc42 or Rac1.
The preceding data (Figures 4 and 5A–5C) have provided
evidence (i) that Merlin plays a critical role in the inhibitory action
of Erbin; and (ii) that Erbin functions via a Rho protein-dependentpmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevier Inc. 437
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Merlin and Erbin Coregulate PAK2 ActivityFigure 4. Erbin Overexpression Prevents Profibrotic TGF-b Signaling
(A) Quiescent AKR cells or AKR clones stably transfected with Erbin (A-Erbin) alone or in conjunction with nontargeting siRNA (NT) or siRNA against Merlin
(si-Merlin) were left untreated () or stimulated (+) for 45 min with 10 ng/ml TGF-b. Cell lysates were assessed for PAK2 kinase activity (1st panel) or the indicated
proteins by western analysis.
(B) The same clones as in (A) as well as one expressing empty vector (A-Hygro) were grown to confluency and serum starved overnight. After 48 hr of treatment
with (+) or without () 10 ng/ml TGF-b, representative areas were photographed at a magnification of 203 by phase microscopy.
(C) (Left) Soft agar colony formation was performed on the indicated cultures as described. Representative areas were photographed at a magnification of 203
after 10 days in culture. (Right) The mean ± SD of three independent soft agar assays each done in triplicate is provided.
(D) Transcriptional response of two non-Smad (FN-lux and Col1-lux) and Smad-dependent (SBE-lux and 3TP-lux) reporters in the indicated clones after a 24 hr
treatment in the absence (white bars) or presence (black bars) of 10 ng/ml TGF-b. Fold induction relative to untreated AKR for FN (fibronectin), Col I (type 1
collagen), SBE (Smad Binding Element), and 3TP represent the mean ± SD of three separate experiments, each performed in triplicate.mechanism(s), respectively. To integrate these two findings, the
requirement for Merlin in the inhibition of PAK2 kinase activity via
preventing Cdc42 and Rac1 binding was investigated. A-Erbin
cells were isolated stably expressing control or Merlin-targeting
siRNA. As shown in Figure 5D, Merlin knockdown abrogated the
inhibitory effectof Erbin on TGF-b-stimulated PAK2 kinase activity
and Rho protein binding (compare lanes 2, 4, and 8 in the 1st, 3rd,
and 6th panels). Consistent with earlier data (Figure 5C), loss of
Merlin did not impact Cdc42 or Rac1 GTP loading. Thus, Erbin438 Developmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevieand Merlin coordinately function to regulate Rho-dependent
PAK2 signaling.
Erbin Reduction Is Not Sufficient for PAK2 Activation
without Upstream Signaling Events
Data have been presented showing two significant differences
between mesenchymal and epithelial cultures. First, although
TGF-b activates PAK2 in fibroblasts, this does not occur in
epithelia (Wilkes et al., 2003); second, the epithelial-enrichedr Inc.
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Merlin and Erbin Coregulate PAK2 ActivityFigure 5. Erbin Inhibits PAK2 Kinase Activity via Dissociation of Active Cdc42/Rac1 from PAK2
(A) Parental AKR-2B cells and an Erbin-overexpressing AKR-2B clone (A-Erbin) were left untreated () or stimulated (+) with TGF-b for 45 min (10 ng/ml), PDGF AB
for 20 min (25 ng/ml), methylglyoxal (MG) (10 mM) for 24 hr, NaCl (0.7 M) for 30 min, or sphingosine (100 mM) for 60 min. PAK2 kinase activity (top panel) or PAK2
(middle panel) and Erbin (bottom panel) protein expression was determined.
(B) (Left) AKR-2B and A-Erbin cells were transiently transfected with either wild-type eGFP-PAK2 or constitutively active eGFP-PAK2 (eGFP-PAK2 CA) and left
untreated () or stimulated (+) with TGF-b (10 ng/ml) for 45 min. Normalized lysates were assayed for PAK2 activity after GFP immunoprecipitation (top panel) or
eGFP-PAK2 and PAK2 expression (bottom panel) by western blot. (Right) AKR or A-Erbin cultures were transiently transfected (+) with constitutively active (CA)
Cdc42 or Rac1. PAK2 kinase activity (top panel) or western analysis for the indicated protein was determined 24 hr later. Mock refers to nontransfected cells.
(C) (Left) AKR cells or AKR clones stably transfected with empty vector (A-Hygro) or Erbin (A-Erbin) were treated for 45 min with (+) or without () 10 ng/ml TGF-b
and were assayed for activated Cdc42 (top), PAK2-bound Cdc42 (2nd from top), and total Cdc42 (3rd from top) (Wilkes et al., 2003). Rac1 was examined in a similar
manner (bottom three panels). (Right) AKR cells were grown to confluence, serum starved overnight, and either left untreated () or stimulated (+) with 10 ng/ml
TGF-b for 45 min. Lysates were prepared and assayed for activated Cdc42 (top), PAK2-bound Cdc42 (2nd from top), and total Cdc42 (3rd from top) after the addi-
tion of 0, 2.5, 5.0, 10, or 20 mg purified Erbin. Rac1 was examined in a similar manner (bottom three panels).
(D) AKR cells or A-Erbin alone or in conjunction with nontargeting (NT) or siRNA against Merlin (si-Merlin) were left untreated () or stimulated (+) for 45 min with 10
ng/ml TGF-b. Cell lysates were assessed for the indicated activities or protein.protein Erbin has a critical role in regulating this cell type
difference (Figures 2–5). These findings generate the following
question: Would Erbin loss be sufficient for epithelial cells to
activate PAK2? To address that issue, human A549 cells
were generated stably expressing siRNA against Erbin.
Knockdown of Erbin had no effect on basal or TGF-b-stimu-
lated PAK2 activity, Cdc42 activation, Cdc42 binding PAK2,
or morphologic changes (Figures 6A and 6B). Since A549
cells do not activate the upstream components (i.e., Rho
proteins) necessary for PAK2 activation, it was not unex-
pected that Erbin loss would be ineffective in inducing PAK2
kinase activity.DeveloIn contrast to A549 or Mv1Lu cells (Figure 6A) (Wilkes et al.,
2003, 2005), after TGF-b stimulation the NMuMg murine
mammary epithelial cell line activates Rho proteins and
undergoes an epithelial-to-mesenchymal transition (EMT) (Bakin
et al., 2000). Since this would seem to represent an ideal precon-
dition for epithelial activation of PAK2, we examined the effect of
Erbin or Merlin knockdown in NMuMg cells. In agreement with
previous publications (Bakin et al., 2000; Wilkes et al., 2003),
TGF-b stimulated GTP loading of Cdc42, yet was unable to
induce PAK2 kinase activity (Figure 6C). This inability to activate
PAK2 is directly related to the inhibitory actions of Erbin
and Merlin, as siRNA to either resulted in TGF-b-dependentpmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevier Inc. 439
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Merlin and Erbin Coregulate PAK2 ActivityFigure 6. Epithelia Regulate PAK2 Activity by Multiple Means, including Rho Protein Activation and Erbin/Merlin
(A) The human epithelia A549 line and a clone stably expressing siRNA against Erbin (A549 siErbin) were left untreated () or stimulated with 10 ng/ml TGF-b for
45 min. After cellular lysis, the indicated activity or expressed protein was determined as described.
(B) A549 and A549 siErbin cells were cultured in the absence () or presence (+) of 10 ng/ml TGF-b for 48 hr, and representative areas were photographed (203).
(C) NMuMg or clones stably expressing constitutively active PAK2 (N-PAK2 CA), dominant-negative PAK2 (N-PAK2 DN), siRNA against Erbin (N-siErbin), siRNA
against Merlin (N-siMerlin), or siRNA against Erbin and treated with adenovirus (MOI 200) expressing dominant-negative PAK2 (N-siErbin+PAK2 DN) were stim-
ulated for 45 min ± 10 ng/ml TGF-b and assayed for the indicated activity or protein.
(D) Parental NMuMg cells and the clones discussed in (C) were grown to confluence and incubated in the absence () or presence (+) of TGF-b for 24 hr. After PBS
wash, representative areas were photographed at 203 magnification.
(E) Quantitation of attached (left) and viable (right) cells from indicated cultures treated in the absence () or presence (+) of TGF-b for 48 hr. Nontargeting
constructs were without effect (data not shown). Data represent mean ± SD of duplicate samples and are representative of three experiments.PAK2 activation (Figure 6C, compare the signal in the top panel
of lanes 2, 8, and 10), accompanied by the expected
morphological and survival defects (Figure 6D), which are, in
turn, rescued by dominant-negative PAK2 (Figures 6D and 6E).
The preceding data are consistent with a model whereby Erbin
and Merlin function downstream of Cdc42/Rac1 to prevent
PAK2 activity in those epithelia that activate Rho proteins in
response to TGF-b.440 Developmental Cell 16, 433–444, March 17, 2009 ª2009 ElsevieDISCUSSION
A fundamental question in understanding TGF-b action is how
one growth factor can induce such distinct responses as growth
promotion and growth inhibition depending upon the cell context.
To underscore the biological relevance of this complexity,
whereas normal epithelia are routinely growth arrested in
response to TGF-b, during the process of tumor progressionr Inc.
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stimulated (Gobbi et al., 2000) and/or dependent upon TGF-b
secreted by stromal elements (Bhowmick and Moses, 2005) or
the tumor itself (Tang et al., 2003).
It has previously been reported that TGF-b activates distinct
signaling targets dependent upon the cell type stimulated. For
instance, although TGF-b induces PAK2 and c-Abl kinase activity
in a subset of mesenchymal cultures, there is no detectable
response when epithelial lines are similarly treated (Daniels
et al., 2004; Wilkes and Leof, 2006; Wilkes et al., 2003). Moreover,
PAK2 and c-Abl have beenshown to be critical for TGF-b-directed
responses such as soft agar colony formation and morphologic
transformation (Daniels et al., 2004; Wilkes and Leof, 2006; Wilkes
et al., 2003), and these in vitro surrogates have been extended to
various animal models of organ fibrosis (Azuma et al., 2007;
Chaudhary et al., 2006; Daniels et al., 2004; Wang et al., 2005)
and, in at least one case, to a Phase II clinical trial testing the effi-
cacy of imatinib mesylate versus placebo in the treatment of
idiopathic pulmonary fibrosis (http://clinicaltrials.gov/ct/show/
NCT00131274?order = 1). These findings underscore the need
to address the mechanisms regulating this cell tropism. As an
initial undertaking to that question, the current study was per-
formed. The results show that epithelial cells prevent PAK2
activity via the coordinate action of Erbin and the NF2 tumor
suppressor Merlin (Figures 3–6).
The interaction between PAK proteins and Merlin is complex;
various reports document Merlin as either a substrate of acti-
vated PAKs (Kissil et al., 2002; Okada et al., 2005; Xiao et al.,
2002) or an inhibitor (Kissil et al., 2003; Xiao et al., 2005).
Although our findings confirm the physical interaction between
Merlin and activated PAK2 (Figure 2A), the consequential role
Merlin plays in TGF-b signaling depends upon the presence or
absence of the binding partner, Erbin. In the absence of Erbin,
Merlin is phosphorylated and (presumably) inactivated in
response to TGF-b. However, if Merlin is bound to Erbin, it
cannot be phosphorylated in vitro or in vivo, and the Erbin-Merlin
complex is then capable of inactivating already activated PAK2
(Figures 3A, 4, 5D, and 6). In agreement with this, TGF-b stimu-
lates Merlin phosphorylation in fibroblasts (i.e., not bound to
Erbin), but not epithelial cells (Figure 2A).
In addition to a role for Merlin, PAK2 kinase activity by TGF-b is
also controlled by Cdc42/Rac1 and PI3K (Wilkes et al., 2003,
2005). We found no effect of Erbin or the Erbin-Merlin complex
on Cdc42/Rac1 GTP loading (Figures 5C, 5D, and 6C) or Akt
phosphorylation as a readout of PI3K (data not shown). As the
Erbin-Merlin complex induced a loss in the level of Cdc42/Rac1
bound to PAK2 (Figures 5C and 5D), this indicates that the Erbin
complex competitively or sterically removes GTP-bound Rho
proteins from PAK2. This is analogous to the finding that Erbin
inhibits the ability of activated Ras to transmit downstream
signals by disrupting the Ras-Sur8-Raf association (Dai et al.,
2006). Although it is unclear why pulling activated Cdc42/Rac1
off PAK2 leads to PAK2 deactivation, it indicates that PAK2
activity is regulated in a more nuanced manner than previously
thought. Interestingly, although Erbin uncouples Cdc42/Rac1
association with PAK2, the conformational change brought about
by Cdc42/Rac1 binding is not sufficient to recruit Merlin and
requires additional TGF-b-regulated signals (Figure S2). Although
the nature of these requirements is unknown, our preliminary dataDeveloindicate that they are dependent upon PI3K and phosphatase
activity as well as the Merlin-binding and PDZ domains of Erbin
(unpublished data, M.C.W. and E.B.L.). These findings clearly
indicate that PAK2 is regulated by a number of activities;
however, the importance of Erbin in this control should not be
underestimated, as it alone is capable of inhibiting PAK2 when
expressed in fibroblasts (Figures 3–5).
As stated above, Erbin expression had no impact on the acti-
vation of the upstream mediators of PAK2 activation, Cdc42/
Rac1 or PI3K. The activation of these factors, like PAK2, occurs
primarily in fibroblast, and not epithelial, cell types. We have
determined that in A549 cells, a human epithelial line that also
fails to activate these upstream mediators (Wilkes et al., 2003),
manipulation of Erbin or Merlin levels has no effect on the inability
of these cells to activate PAK2 (Figure 6A). This implies that there
are a number of regulatory mechanisms that dictate whether
a cell can activate PAK2 in response to TGF-b. In agreement
with this, in epithelial cells expressing a constitutively active
PAK2, instead of an expected cellular response reminiscent of
a fibroblast (i.e., proliferation, morphological transformation),
TGF-b stimulation resulted in gross morphologic alterations
and catastrophic population collapse (Figures 1B and 6D). This
would suggest that if PAK2 activity provides a necessary compo-
nent to the migratory and/or metastatic response seen during
EMT and carcinoma progression, it is likely a late event. Again,
it is useful to consider the NMuMg cell line, in which TGF-b acti-
vates GTPases and indeed frank EMT, in the absence of PAK2/
c-Abl pathway activity. It would therefore seem likely that the
latter pathway controls events subsequent to EMT. In that regard,
Erbin deregulation has been reported in cervical tumors, colon
carcinomas, glioblastomas, and BRCA1-overexpressing cells
(Atalay et al., 2002; Dardousis et al., 2007; Huang et al., 2006),
all of which display aberrant TGF-b signaling that is recognized
to play a significant role in disease progression. It is unknown
whether this corresponds to a similar loss in PAK2 regulation.
A role for PAK2 in TGF-b-mediated EMT might have seemed
likely in light of PAK2’s effects on cytoskeletal rearrangement
and cell migration. However, as alluded to in the previous para-
graph, investigation of this issue in the NMuMg model of EMT
showed no role for PAK2 in the morphologic alterations or effect
on EMT markers, including vimentin, E-cadherin, or N-cadherin
observed after TGF-b stimulation (Figure S3). In addition, PAK2
was not activated, nor was the expression profile of PAK2,
Merlin, or Erbin modified over the course of 72 hr of TGF-b treat-
ment (Figure S3). Consistent with our previous data showing
a role for Erbin and Merlin in preventing PAK2 activation, siRNA
to either did result in robust PAK2 activity after TGF-b addition
(Figure 6C). Moreover, activation of PAK2 signaling in NMuMg
cells generated a similar loss of viability as that observed in
Mv1Lu cells (Figures 1B, 6D, and 6E). These findings support
the proposal that the acquisition of a stimulatory response to
TGF-b in epithelia requires (at a minimum) a positive signal to
activate upstream components including Rho proteins and
PI3K, loss of a downstream negative regulator such as Erbin or
Merlin, and the ability to overcome PAK2-mediated cell death.
The current study addresses two primary points. First, it
provides an explanation for the seemingly contradictory findings
that Merlin can function as a PAK2 substrate or inhibitor; and,
second, a potential mechanism for cell-type-specific PAK2pmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevier Inc. 441
Developmental Cell
Merlin and Erbin Coregulate PAK2 ActivityFigure 7. Model Depicting Coordinate Regulation of PAK2 by Rho Proteins and Erbin/Merlin
A cartoon depicting known mechanisms restricting PAK2 activation by TGF-b. In most epithelia (i.e., Mv1Lu and A549 cells; left column), PAK2 kinase activity is
prevented through an inability of TGF-b to activate Cdc42 or Rac1 (restriction point 1). Alternatively, in epithelial cultures such as NMuMg cells that have bypassed
the initial restriction point (i.e., activate Rho proteins), PAK2 remains inactive due to an interaction of Erbin and Merlin with GTPase-activated PAK2 (restriction
point 2; middle column). In both the left and middle panels, the growth-inhibitory function of Merlin would be intact. Although the inhibitory complex is represented
by an Erbin/Merlin heterodimer, the stochiometry and overall composition are unknown. Fibroblasts (right column), however, overcome both restrictions by acti-
vating Cdc42 and Rac1 after TGF-b treatment (Figure 5C) and having low Erbin expression (Figure 2C), respectively, resulting in Merlin phosphorylation/inacti-
vation by PAK2.signaling by TGF-b is defined. For instance, in mesenchymal
cells, low Erbin levels and PAK2 activation would result in Merlin
phosphorylation/inactivation and propagation of the growth-
promoting actions of TGF-b observed in tissue fibrosis, soft
agar colony formation, and (potentially) late stages of tumor
progression. Conversely, in epithelial cells in which Erbin expres-
sion is high, this would generate an Erbin-Merlin complex and
effectively remove free Merlin as a potential PAK2 target. As
PAK2 phosphorylation is believed to diminish Merlin’s tumor-
suppressive activity (Surace et al., 2004), complexing with Erbin
would maintain this function in epithelia as a component of the Er-
bin-Merlin inhibitory complex. A cartoon depicting these events is
provided as Figure 7. In both situations (free Merlin and Erbin-
Merlin), Merlin is recruited to PAK2 once the kinase is activated.
This leads in one (fibroblasts) to the propagation of a growth-
promoting signal and in the other (epithelia) to dissolution of the
PAK2/GTPase complex and termination of the signal.
Collectively, we provide evidence to support a role for the level
of Erbin modulating the ability of TGF-b to propagate PAK2
signaling. High Erbin expression leads to an increased abun-
dance of Erbin-Merlin and a reduced level of free-Merlin, and
therefore changes the role of Merlin from one of a PAK2
substrate to PAK2 inhibitor. The mechanism for inhibition by
the Erbin-Merlin complex involves, but may not be limited to, dis-
rupting the association between PAK2 and GTP-bound Cdc42/
Rac1. How Erbin mechanistically deactivates PAK2 is unclear;
however, if another factor(s) is required, it must be present in
both fibroblast and epithelial cell lines, as expression/addition
of Erbin alone is sufficient to cause PAK2 inhibition in fibroblasts
(Figures 3–5). Current efforts are designed to determine the442 Developmental Cell 16, 433–444, March 17, 2009 ª2009 Elsevienature of these other components required for the generation
and/or action of the inhibitory complex. It is anticipated that
answers to these questions will lead to a better understanding
of TGF-b signaling during fibrosis and carcinoma progression.
EXPERIMENTAL PROCEDURES
Cell Culture
AKR-2B (AKR) and Mv1Lu (M64) cells were grown in high-glucose Dulbecco’s
modified Eagle’s medium (DME) supplemented with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT). Empty vector and Erbin-expressing AKR clones
(A-Erbin) were generated by Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
transfection followed by selection of individual clones resistant to 300 mg/ml
hygromycin (Invitrogen, Carlsbad, CA) and expressing high Erbin levels by
western analysis. A-Erbin cells were subsequently infected with lentivirus
expressing shRNA to Merlin and selected in 1 mg/ml puromycin (Sigma, St.
Louis, MO). Constitutively active eGFP-PAK2 (T402E) clones were generated
as described above; however, positive clones were selected by flow cytometry
examining GFP expression. NMuMg cell clones expressing active PAK2 or
shRNAs were similarly generated. Unless otherwise stated, AKR cells were
plated at 2.5 3 106, whereas M64 and NMuMg cells were plated at 3.0 3
106 in p100 dishes and incubated overnight at 37C to achieve confluency
before serum starvation (16–24 hr) and stimulation. Adenoviral constructs
(multiplicity of infection [MOI] of 200 for AKR-2B cells and MOI of 50–100 for
all other lines) were added with the serum-free media and were retained
through stimulation. Cell viability was determined by Trypan blue exclusion.
Lysate Mixing
AKR-2B and Mv1Lu cells were grown to confluence and washed in cold PBS at
4C. Pellets were collected and snap frozen prior to 20C storage. To
prepare lysates, cells were incubated in kinase lysis buffer (50 mM Tris
[pH 7.4], 5 mM EDTA, 250 mM NaCl, 0.1% Triton X-100, 50 mM NaF, 0.1
trypsin inhibitor unit of aprotinin per milliliter, 50 mg/ml phenylmethylsulfonyl
fluoride, 100 mM sodium vanadate, 1 mg/ml leupeptin) for 30 min at 4C withr Inc.
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tants were removed and, after protein normalization, gently mixed at the indi-
cated ratios for 5 min at 4C before further analysis. In cases in which lysates
were first immunodepleted, prior to mixing normalized lysates were first incu-
bated overnight with specific antibody at 4C, followed by Protein A/G-
Agarose. This was repeated two additional times with either the same antibody
or an antibody recognizing a different epitope.
Western Blot
Confluent cultures were treated overnight in serum-free (AKR-2B) or 0.1%
FBS/DME (other cell lines). After the addition of growth factors for the indicated
times, cells were lysed in kinase lysis buffer, and equivalent protein was pro-
cessed for western analysis. Unless noted otherwise, blots were incubated
overnight with primary antibody (4C), washed (10 mM Tris [pH 7.4], 0.1%
Tween, 140 mM NaCl), and then treated for 45 min at 25C with secondary
antibody prior to washing and visualization with ECL reagent from Amersham
(Piscataway, NJ). Antibodies used were from Upstate Biotechnology (Lake
Placid, NY; anti-Cdc42, 05-542; anti-Rac1, 05-389, anti-Smad2, 06-829),
Roche (Indianapolis, IN; anti-Myc, 11667149001; anti-GFP, 1814460), Calbio-
chem (San Diego, CA; anti-phospho-Smad2, 618042), Chemicon Interna-
tional, Inc. (Temecula, CA; anti-GAPDH, MAB374), Zymed Laboratories-
Invitrogen (Carlsbad, CA; anti-Smad3, 51-1500), Santa Cruz Biotechnology
(Santa Cruz, CA; anti-PAK1, sc-882; anti-PAK2, sc1872; anti-TbR1, sc-398;
anti-Merlin, sc-331; anti-Erbin, sc-30054 and sc-13249), or Cell Signaling
(Beverly, MA; anti-PAK2, #2608; anti-Merlin2, #9168). A rabbit phospho-
Smad3 antibody to the peptide COOH-GSPSIRCSpSVpS was generated in
our laboratory. Secondary goat anti-mouse or donkey anti-rabbit antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA; sc-2005)
and Amersham (Piscataway, NJ; NA934V), respectively.
Coimmunoprecipitations
Cells were grown to confluence in 10% DME and were serum starved over-
night. After the indicated treatment, cells were lysed in modified kinase lysis
buffer (pH 6.8) for 30 min at 4C. Normalized lysates were then incubated over-
night at 4C in the presence of antibody before collection of the immune
complex by using Protein A- or Protein G-Agarose (Upstate Biotechnology,
Lake Placid, NY). After washing, proteins were submitted to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were silver
stained or transferred to PVDF and processed for western analysis. Silver
staining was performed by utilizing the Silverquest staining kit (Invitrogen, CA).
Soft Agar Assay
Bottom plugs (1 ml) composed of 0.8% Sea Plaque-agarose (FMC Bioprod-
ucts, Rockland, ME), 10% FBS/DMEM were cast in 35 mm plates. Top plugs
(1 ml) contained 0.4% agarose, 10% FBS/DMEM, and 23 104 of the indicated
cells in the presence or absence of 10 ng/ml TGF-b. After 10 days at 37C, the
number of colonies greater than 100 mm in diameter were counted by using an
Optronix Gel Count (Oxford Optronix Ltd, UK).
Kinase Assays
Cultures were treated as indicated and lysed for 30 min at 4C in 750 ml kinase
lysis buffer. Extracts were clarified, and equivalent protein (500–700 mg) was
incubated overnight at 4C with antibody. Immune complexes were collected
with protein G-Agarose and washed twice in kinase lysis buffer and twice in
kinase buffer (50 mM Tris [pH 7.4], 10 mM MgCl2, 1 mM dithiothreitol) prior
to incubation in 50 ml kinase buffer containing 5 mM ATP, 5 mCi [g-32P]ATP
per ml and 5 mg substrate (MBP for PAK kinase assays and GST-Smad2 for
type I TGF-b receptor kinase assays). The kinase assay was allowed to
proceed for 10 min at 37C, stopped with 50 ml 23 Laemmli buffer, submitted
to SDS-PAGE, and visualized by autoradiography.
Protein Purification and Reporter Assays
Smad2, Merlin, and Erbin purification was carried out as per the manufac-
turer’s recommendation by using Catch and Release v2.0 (Upstate Biotech-
nology, Lake Placid, NY). Normalized luciferase activity was determined after
transient transfection (Fugene 6, Roche) with 2 mg luciferase vector plus 0.5 mg
CMV-b-galactosidase as described (Anders and Leof, 1996).DeveloCdc42/Rac1 Activation and PAK2 Association
Cultures were grown to confluence in 10% DME and serum starved overnight.
After treatment with 10 ng/ml TGF-b for 45 min, cells were lysed in either 13
Mg2+ lysis/wash buffer (Upstate) with leupeptin, aprotinin, sodium fluoride,
and sodium vanadate (Cdc42/Rac1 activation assays) or modified kinase lysis
buffer ([pH 6.8] PAK2 association assays) for 30 min at 4C. Rho protein acti-
vation was performed as recommended (Upstate, Cdc42 Activation Assay
Kit 17-286) with the modifications that antibody incubation proceeded for 2 hr,
followed by six washes before final Laemmli buffer suspension. PAK2/Rho
protein association studies were performed after overnight PAK2 immunopre-
cipitation (Santa Cruz, sc-7117) and western blot for Cdc42 or Rac1.
Morphological Transformation
The indicated parental and AKR-2B clones were plated at 2.53 105 clones per
6-well dish and incubated at 37C for 24 hr. Confluent cultures were placed in
serum-free DME for 24 hr and either left untreated or stimulated with 10 ng/ml
TGF-b for 48 hr. Documentation was by phase-contrast microscopy (magnifi-
cation, 203). Mv1Lu cells expressing constitutively active PAK2 were similarly
plated. After incubation at 37C for 24 hr in the presence of doxycyclin (1 mg/ml)
to induce expression of the recombinant protein, cultures were treated and
processed as for AKR-2B cells. A549 human epithelial cells and A549 stably
expressing siRNA to Erbin (A549-siErbin) were treated as described above
before being placed in 0.1% FBS-DME for 24 hr. The indicated cultures
were then stimulated with 10 ng/ml TGF-b for 48 hr. NMuMg cells were plated
at 2.0 3 105 cells per 6-well dish and were incubated in 10% FBS-DME sup-
plemented with 5 ng/ml EGF and 10 mg/ml insulin. Clones expressing siErbin
were further treated with 200 MOI adenovirus expressing dominant-negative
PAK2 (N-siErbin + PAK2 DN). After 48 hr, cells were either left untreated or
stimulated with 10 ng/ml TGF-b for the indicated times and documented by
phase-contrast microscopy (magnification, 203).
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